Managing Vesicant Extravasations. Oncology Nursing Consultant, River Ridge, Louisiana, USA
|
|
- Percival Gaines
- 5 years ago
- Views:
Transcription
1 The Oncologist The Community Oncologist Managing Vesicant Extravasations LISA SCHULMEISTER Oncology Nursing Consultant, River Ridge, Louisiana, USA Key Words. Vesicant extravasation Vesicant extravasation treatment Tissue necrosis Disclosure: L.S. has acted as a consultant to TopoTarget USA (manufacturer of Totect, which is mentioned in this article), and has received an honorarium from Baxter (manufacturer of Hylenex, which is mentioned in this article) for participation in a focus group. No other potential conflicts of interest were reported by the author, planners, reviewers, or staff managers of this article. LEARNING OBJECTIVES After completing this course, the reader will be able to: 1. Describe how vesicant chemotherapy drugs can extravasate from implanted ports. 2. Recommend procedures to obtain a blood return from central venous access devices. 3. Evaluate the signs and symptoms of a vesicant extravasation. 4. Administer the FDA-approved vesicant extravasation treatments and antidotes. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit at CME.TheOncologist.com ABSTRACT Extravasation is an unusual but potentially severe complication of vesicant chemotherapy administration. Some extravasation injuries prompt litigation and the oncologist s actions, or lack of action, are scrutinized in the courtroom. This article presents advice and recommendations for treating patients who receive vesicants and includes a discussion of FDA-approved vesicant extravasation treatments and antidotes. The Oncologist 2008;13: INTRODUCTION Vesicant extravasation injuries can occur in patients receiving chemotherapy despite best efforts to prevent them. There are several things oncologists can do to mitigate against both the risk of legal action and the extent of tissue damage. BEST PRACTICES IN THE CLINIC FOR THE ONCOLOGIST AND THE TREATMENT TEAM 1. Inform patients of the risk for vesicant extravasation. Although the risk for vesicant extravasation is very low, estimated to be in the range of 0.01% 6% [1, 2], patients need to be informed that extravasation may occur each time they receive a vesicant. When a chemotherapy protocol or treatment plan is initially explained to a patient, there is a tendency to emphasize the more common risks, such as myelosuppression, nausea and vomiting, hypersensitivity, and fatigue. The risk for vesicant extravasation is sometimes overlooked or underemphasized. However, in the courtroom, it is recognized that a risk for vesicant chemotherapy is extravasation, and the question of whether or not patients were fully informed of this risk is considered. In some cases, patients have Correspondence: Lisa Schulmeister, R.N., M.N., A.P.R.N.-B.C., O.C.N., F.A.A.N., 282 Orchard Road, River Ridge, Louisiana 70123, USA. Telephone: ; Fax: ; LisaSchulmeister@hotmail.com Received October 8, 2007; accepted for publication January 12, AlphaMed Press /2008/$30.00/0 doi: /theoncologist The Oncologist 2008;13:
2 Schulmeister 285 Figure 1. Doxorubicin-induced tissue necrosis that occurred after a needle dislodged from an implanted port. responded by saying nobody ever told me this could happen. 2. Recognize that implanted ports reduce they do not eliminate the risk for extravasation. Oncologists often recommend port insertion because of the sclerosing effect of vesicants and other chemotherapy drugs on the peripheral veins. Although implanted ports reduce the risk for extravasation, vesicant extravasations can still occur. Noncoring (e.g., Huber) needles may be incompletely placed into or dislodge from the port septum (Fig. 1). Formation of a thrombus or fibrin sheath at the tip of the catheter can cause backtracking of the vesicant along the catheter to the venotomy site where the vesicant can leak into the tissue. Perforation of the superior vena cava, catheter fracture, and separation of the port from the catheter also can lead to vesicant extravasation into the tissue or other areas such as the mediastinum or pleural space [3, 4]. 3. Never permit or approve the use of an implanted port that flushes easily but does not have a blood return. If a port lacks a blood return but flushes easily, vesicant chemotherapy should not be given without further investigation; a blood return or other evidence of correct port placement and patency (e.g., dye study) is needed before a vesicant is administered. The patient should be placed in a supine or lateral decubitus position and another attempt made to obtain a blood return. This simple maneuver is successful in many patients, especially outpatients, who are seated upright during the initial attempt to obtain a blood return. If repositioning is not successful, a 10-ml syringe with normal saline can be used with a gentle push-pull motion to flush the port. In a study conducted in Belgium, a blood return was achieved in 53% of 8,685 ports that lacked a blood return after simply changing the patient s position and/or additional flushing [5]. Implanted port catheter tips typically accumulate a coat of fibrin that can act as a one-way valve, permitting infusion Figure 2. X-ray of the cervical spine showing migration and impending fracture of the port catheter. of fluids but not the withdrawal of blood. Catheter tips also can be occluded by thrombi. Instillation of a thrombolytic agent (e.g., tissue plasminogen activator [TPA]) should restore a blood return from the port when partial (withdrawal occlusion) or total occlusion occurs. In the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial, alteplase (TPA injection) restored catheter function 90% of the time [6]. A chest x-ray can ascertain proper catheter placement and may detect a fractured or severed catheter. However, chest x-ray does not ascertain catheter patency. A chest x- ray that includes the cervical spine is indicated when there is suspicion of catheter migration (e.g., when patients feel or hear something on one side of the neck) (Fig. 2). A dye study (cathetergram) assesses both placement and patency. Extravasations can occur when catheters detach from or break at the junction of the catheter and port septum, when catheters fracture, and, rarely, when catheters are nicked, sliced, or pierced prior to or during port insertion (Fig. 3). Vesicant administration should only proceed when there is a blood return from the port or there is other evidence of correct placement and patency, such as a dye study. 4. Know that despite nurses best efforts, vesicant extravasations sometimes occur. Although nurses take great care to prevent extravasations by closely monitoring patients during vesicant administration, extravasations sometimes occur. Patient movement may cause a peripheral i.v. catheter to perforate the vein wall. Accidental tugging on i.v. tubing may cause the catheter to dislodge. Mechanical failure of the vascular access device is yet another example
3 286 Managing Vesicant Extravasations Figure 4. Doxorubicin extravasation prior to Totect treatment (left) and following treatment (right). Tissue necrosis did not occur. The small pink crosshatches are the sites where tissue biopsies were taken to confirm anthracycline extravasation TopoTarget, used with permission. Figure 3. Dye study of implanted port showing leakage of the dye into the tissue near the port septum. of a situation that cannot always be prevented; instead, extravasations must be detected promptly. 5. Admit that a vesicant extravasation has occurred. Extravasation is a known risk of vesicant administration. When this complication occurs, or is suspected, be truthful and avoid minimizing the situation or worse, fabricating an explanation for the extravasation. 6. Avoid the blame game. Patients often seek explanations for why their extravasations occurred. It is tempting to criticize the nurse for poor technique or imply that the patient moved or in some way caused or contributed to the extravasation occurring. Instead, various factors should be examined, and most importantly, the information that was present at the time of the extravasation must be considered. Once an extravasation injury is apparent, Monday morning quarterbacks can find fault, point fingers, and, with great authority, state what should have been done differently. However, what information was present at the time of the extravasation? Was a blood return obtained? How and how often was the patient monitored? Was the staffing level sufficient to care for the number and acuity of the patients treated that day? Did anything unusual occur (e.g., inadvertently tugging on the tubing)? Did the patient complain of pain at the i.v. site? Each extravasation is unique and must be considered in the context in which it occurs. Like medication errors, there are usually multiple factors that cause or contribute to the occurrence of a vesicant extravasation. 7. Discard the it can t happen here mentality. Extravasations can occur wherever vesicants are administered, even in settings where highly experienced oncology nurses give hundreds of doses of vesicants each day. And just because an extravasation hasn t ever occurred in a particular facility doesn t mean that an extravasation can t occur. One could occur this afternoon or tomorrow. Extravasations cannot always be prevented. 8. Be familiar with the signs and symptoms of a vesicant extravasation. Fortunately, vesicant extravasations do not occur every day. In fact, they occur so rarely that some oncologists have never seen one personally. Signs and symptoms of a vesicant extravasation include swelling (common), redness, discomfort (may or may not be present and is often described as stinging or burning), lack of a blood return from the i.v. device, and an infusion that slows or stops [7 9]. When in doubt, it is best to presume that an extravasation has occurred and initiate appropriate treatment. Initial workup following a suspected vesicant extravasation should include estimating the amount and concentration of the vesicant that may have extravasated into the tissue, evaluating the symptoms reported by the patient, assessing the administration site (including measuring and photographing the area in accordance with institutional protocol), and assessing the extremity (if applicable) for range of motion and discomfort with movement. Treatment of the extravasation should then be initiated promptly. TREATMENT OPTIONS FOR VESICANT EXTRAVASATIONS Oncologists practicing in the 1970s likely recall the early published reports and photographs of vesicant extravasation injuries. Despite a significant amount of research (mostly animal) on antidotes and treatments, extravasation management until recently was not much different than it was 30 years ago. Anthracycline (e.g., daunorubicin, doxorubicin, epirubicin, idarubicin) extravasations have been initially managed by cooling the area (ice packs), and the ensuing tissue necrosis generally has required debridement and skin grafting or flap placement. Plant alkaloid
4 Schulmeister 287 (vincristine, vinblastine, vinorelbine) extravasations have been managed by heat application and local injection of hyaluronidase; however, in , hyaluronidase was commercially unavailable [10]. In December 2005, the FDA approved Hylenex recombinant (hyaluronidase human injection, Baxter, Deerfield, IL) for use as an adjuvant agent to increase the absorption and dispersion of other injected drugs. Hyaluronidase increases the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular matrix of connective tissue. Hylenex recombinant is a purified preparation of the enzyme recombinant human hyaluronidase. Other formulations of hyaluronidase are derived from animal products. Amphadase (Amphastar Pharmaceuticals, Rancho Cucamonga, CA) is a bovine-derived preparation and Vitrase (ISTA Pharmaceuticals, Irvine, CA) is an ovine-derived preparation [10]. Hyaluronidase is locally injected into the extravasation sites of plant alkaloids. A 1-ml solution of hyaluronidase is injected as five 0.2-ml injections using a 25-gauge or smaller needle. The needle is changed with each injection. Hyaluronidase is stored under refrigeration [10]. In September 2007, the FDA approved Totect (dexrazoxane for injection, TopoTarget USA, Rockaway, NJ) for the treatment of extravasation resulting from i.v. anthracycline chemotherapy (Fig. 4). (There is currently no therapeutic equivalent of Totect; see FDA [11].) The mechanism by which dexrazoxane diminishes tissue damage is unknown. Totect is supplied as a treatment kit for single patient use and is a systemic treatment that is infused over 1 2 hours each day for 3 days in a large vein in an area away from the extravasation site (e.g., the opposite arm). Totect dosing is based on the patient s body surface area (BSA), with a dose of 1,000 mg/m 2 given on days 1 and 2 and a dose of 500 mg/m 2 given on day 3. Patients with a BSA of 2m 2 should receive a maximum dose of 2,000 mg on days 1 and 2 and 1,000 mg on day 3. The dose of Totect should be decreased by 50% in patients with creatinine clearance values of 40 ml/minute. Topical cooling, such as ice packs, should be removed for at least 15 minutes prior to, and during, Totect treatment. The patient should be monitored for side effects, including nausea/vomiting, diarrhea, stomatitis, bone marrow suppression, elevated liver enzyme levels, and infusion site burning [12 14]. Mechlorethamine (nitrogen mustard) extravasations have been and continue to be treated with the antidote sodium thiosulfate. Sodium thiosulfate neutralizes mechlorethamine to form nontoxic thioesters that are excreted in urine. The manufacturer of mechlorethamine recommends application of ice for 6 12 hours following the local injection of sodium thiosulfate into the extravasation area. A dose of 2 ml of sodium thiosulfate solution for each milligram of mechlorethamine suspected to have extravasated is injected s.c. into the extravasation site using a 25-gauge or smaller needle. The needle is changed with each injection [15]. Taxane (paclitaxel, docetaxel) extravasations cause mild tissue necrosis, and topical cooling is the only recommended treatment [16]. Patients should be instructed to monitor the extravasation site and report blistering, skin sloughing, fever, chills, and worsening pain at the extravasation site. SUMMARY Vesicant extravasations are a litigious area in oncology practice. Oncologists can reduce the risk for litigation as well as optimize patient care by promptly recognizing and treating extravasations. Advances in vesicant extravasation treatment are improving outcomes for patients; tissue necrosis can now be reduced and, in some cases, entirely prevented. Oncologists need to be aware of vesicant extravasation antidotes and new extravasation treatments, such as Totect, which is indicated for the treatment of anthracycline extravasations. REFERENCES 1 Langstein HN, Duman H, Seelig D et al. Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 2002; 49: Barlock AL, Howser DM, Hubbard SM. Nursing management of adriamycin extravasation. Am J Nurs 1979;79: Bozkurt AK, Uzel B, Akman C et al. Intrathoracic extravasation of antineoplastic agents: Case reports and systematic review. Am J Clin Oncol 2003;26: Schulmeister L, Camp-Sorrell D. Extravasations from implanted ports. Oncol Nurs Forum 2000;27: Goossens S, Jerome M, Stas M. Occlusion in totally implantable vascular access devices: What is its incidence and what actions do nurses take to restore patency? Available at UZRoot/files/webeditor/poster_katherzorg.pdf. Accessed September 26, Ponec D, Irwin D, Haire WD et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: A double-blind placebo-controlled trial the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001;12: Ener RA, Meglathery SB, Styler M. Extravasation of systemic hematooncological therapies. Ann Oncol 2004;15:
5 288 Managing Vesicant Extravasations 8 Polovich M, White JM, Kelleher LO. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice, Second Edition. Pittsburgh, PA: Oncology Nursing Society, 2005: Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: Prevention and treatment. Semin Oncol 2006;33: Schulmeister L. Extravasation management. Semin Oncol Nurs 2007;23: U.S. Food and Drug Administration. Drug Details (Totect). Available at Accessed March 14, Schulmeister L. Totect : A new agent for treating anthracycline extravasation. Clin J Oncol Nurs 2007;11: Mouridsen HT, Langer SW, Buter J et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): Results from two prospective clinical multicentre studies. Ann Oncol 2007;18: Totect (dexrazoxane for injection) [package insert]. Rockaway NJ: TopoTarget USA, Inc., Mustargen (mechlorethamine HCl for injection) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., Stanford BL, Hardwicke F. A review of clinical experience with paclitaxel extravasations. Support Care Cancer 2003;11:
Safe Management of Chemotherapy: Infusion-Related Complications
Safety Deborah K. Mayer, PhD, RN, AOCN, FAAN Editor Downloaded by faranakhaghighi@sbcglobal.net on date 10 25 2017. Single-user license only. Copyright 2017 by the Oncology Nursing Society. For permission
More informationIV Drug Delivery Systems used in Cancer Care
IV Drug Delivery Systems used in Cancer Care Cheri Constantino-Shor, RN, MSN, CRNI Seattle Cancer Care Alliance Nursing Staff Development Coordinator Presentation Objective Describe drug delivery devices
More informationSARASOTA MEMORIAL HOSPITAL
SARASOTA MEMORIAL HOSPITAL TITLE: NURSING PROCEDURE DATE: REVIEWED: PAGES: 03/86 7/18 1 of 13 PS1094 ISSUED FOR: Nursing RESPONSIBILITY: RN Chemo Qualified PURPOSE: To provide the RN with specific steps
More informationComplications Associated With IV Therapy
Occlusion is the partial or complete obstruction of a catheter, which obstructs the infusion of solutions or medications. Occlusions can result from the coagulation of blood (thrombotic) or from obstruction
More informationOverview of CVADs. Type of device commonly used. Dwell time Flushing requirement Associated complications. lumens
Source: Clinical Skills Management of Vascular Access Devices Pre-course handbook. Adapted with permission from NHS Lothian Employee and Education Development Team. Overview of CVADs Type of device Veins
More informationTHE CARE AND MAINTENANCE OF TOTALLY IMPLANTED VENOUS ACCESS DEVICES (PORTS)
Children s Hospital for Wales Department of Paediatric Respiratory Medicine and Cystic Fibrosis THE CARE AND MAINTENANCE OF TOTALLY IMPLANTED VENOUS ACCESS DEVICES (PORTS) This protocol applies to the
More informationThe Impact of Catheter Occlusion in Central Line Associated Bloodstream Infections M A R C H 15, 2017
The Impact of Catheter Occlusion in Central Line Associated Bloodstream Infections D A R C Y DOELLMAN M S N, RN, CRNI, VA - BC M A R C H 15, 2017 LOUISVILLE, KENTUCKY Cincinnati Children s Hospital 642
More informationvascular-access.info/ + 32 (0)
Citation Goossens GA, Kerschaever I, Despierre E, Stas M., (2013), Access of a fully rotated implantable port leads to extravasation.j Vasc Access, vol 14(3), 299-300. Archived version Author manuscript:
More informationIf viewing a printed copy of this policy, please note it could be expired. Got to to view current policies.
If viewing a printed copy of this policy, please note it could be expired. Got to www.fairview.org/fhipolicies to view current policies. Department Policy Code: D: PC-5555 Entity: Fairview Pharmacy Services
More informationExtravasation Management of Non- Chemotherapeutic Agents
Extravasation Management of Non- Chemotherapeutic Agents Sarah M. Martin, PharmD, MBA St John Medical Center Tulsa, OK Objectives Review non-chemotherapeutic agents that can cause extravasation Explain
More informationompanionport Speciality Medical Devices For The Veterinary Community Surgical Suggestions
Speciality Medical Devices For The Veterinary Community suture holes Place the CompanionPort in the subcutaneous port pocket off to one side so that the septum of the port will not lie directly beneath
More informationVaxcel Implantable Ports Valved and Non-Valved. A Patient s Guide
Vaxcel Implantable Ports Valved and Non-Valved A Patient s Guide Vaxcel Implantable Port This pamphlet provides some answers to questions you may have about your implantable port and how to care for it
More informationPeel-Apart Percutaneous Introducer Kits for
Bard Access Systems Peel-Apart Percutaneous Introducer Kits for Table of Contents Contents Page Bard Implanted Ports Hickman*, Leonard*, Broviac*, Tenckhoff*, and Groshong* Catheters Introduction....................................
More informationGuidelines for the Management of Extravasation (Version 5 May 2012)
Guidelines for the Management of Extravasation (Version 5 May 2012) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT NECDAG
More informationIs it Necessary to Verify Blood Return in Monthly Port Flushes?
Is it Necessary to Verify Blood Return in Monthly Port Flushes? Gloria B. Ascoli, RN, CRNI, Amy C. Brown, BSN, RN, Jessica L. Cooper, BSN, RN, Allison N. Crawford, BSN, RN, CRNI Background Research Aims
More informationIntravenous Catheter Complications
Vascular Access Device-Related Infection Inadequate skin antisepsis prior to VAD insertion Acute onset of fever, chills, and hypotension. No other apparent source of Notify Prescriber immediately Obtain
More informationCHEMOTHERAPY NETWORK GROUP POLICY FOR THE MANAGEMENT
CHEMOTHERAPY NETWORK GROUP POLICY FOR THE MANAGEMENT OF ETRAVASATION Policy for the management of extravasation Contents Page number Introduction 3 Definition 3 Prevention 3 Follow up 6 Signs and symptoms
More informationExternal Ref: Andres, D.A., et al. Catheter Pinch-Off Syndrome: Recognition and Management.
Department Policy Code: D: PC-5530 Entity: Fairview Pharmacy Services Department: Fairview Home Infusion Manual: Policy and Procedure Manual Category: Home Infusion Subject: Complications With Intravenous
More informationIf viewing a printed copy of this policy, please note it could be expired. Got to to view current policies.
If viewing a printed copy of this policy, please note it could be expired. Got to www.fairview.org/fhipolicies to view current policies. Department Policy Code: D: PC-5530 Entity: Fairview Pharmacy Services
More informationCentral Venous Access Devices. Stephanie Cunningham Amy Waters
Central Venous Access Devices Stephanie Cunningham Amy Waters 5 Must Know Facts About CVAD s 1) What are CVAD s? 2) What are CVAD s used for? 3) How are these devices put in? 4) What are the complications
More informationMary Lou Garey MSN EMT-P MedFlight of Ohio
Mary Lou Garey MSN EMT-P MedFlight of Ohio Function Prolonged and frequent access to venous circulation Allows for patient to carry on normal life; decrease number of needle sticks Medications, parenteral
More informationCentral Venous Catheter Care and Maintenance (includes catheter troubleshooting guide)
Central Venous Catheter Care and Maintenance (includes catheter troubleshooting guide) A Guide for Patients in the Home Phone Number: Nurse/Contact: Central Venous Catheters This manual is a guide for
More informationIV Fluids. Nursing B23. Objectives. Serum Osmolality
IV Fluids Nursing B23 Objectives Discuss the purpose of IV Discuss nursing interventions in IV therapy Identify complications of IV therapy Differentiate between peripheral line, central line, and PICC
More informationEVOGAM. Information for patients Evogam NZ Patient Brochure Update FA3
EVOGAM Information for patients 11179 Evogam NZ Patient Brochure Update FA3 Information for patients and caregivers about EVOGAM This booklet is designed to help you follow the training you will have been
More informationGuidelines for the Management of Extravasation
Guidelines for the Management of Extravasation (Version 5.5-04 Nov 2016) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More information1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Oncology/Haematology Unit (excluding Paediatrics) Oncologists, Haematologists,
More informationCurraheen, Co. Cork. Guidelines on the Management and Care of Central Venous Access Devices
Curraheen, Co. Cork. Guidelines on the Management and Care of Central Venous Access Devices Date re-approved: 27 th Jan 2015. Version No: 2 Revision Due: 2018 Index code: CLIN028 Disclaimer: The information
More informationATI Skills Modules Checklist for Central Venous Access Devices
For faculty use only Educator s name Score Date ATI Skills Modules Checklist for Central Venous Access Devices Student s name Date Verify order Patient record Assess for procedure need Identify, gather,
More informationSuccessful IV Starts Revised February 2014
Successful IV Starts Revised February 2014 Why Intravenous Therapy? Used for access to the body s circulation Indications: Administer fluids, blood, medications, and nutrition Obtain laboratory specimens
More informationCENTRAL VENOUS ACCESS DEVICES. BETHANY COLTON
CENTRAL VENOUS ACCESS DEVICES. BETHANY COLTON Aims and Objectives To know what central venous access devices (CVAD) are. Types of CVADS used in haematology. To understand why we use them To know the complications
More informationPeripherally Inserted Central Catheter (PICC) Booklet
Aintree University Hospital FT PICC Booklet: a real world example This local booklet is an example used in the NICE medical technology guidance adoption support resource for SecurAcath for securing percutaneous
More informationIV Fluids Nursing B23 Objectives Serum Osmolality 275 to 295 Isotonic
1 IV Fluids Nursing B23 2 Objectives 3 Serum Osmolality Serum osmolality solute concentration of a solution Higher osmolality means greater pulling power for water Normal serum osmolality is 275 to 295
More informationInsertion of a totally implantable vascular access device (TIVAD)
Insertion of a totally implantable vascular access device (TIVAD) What is a TIVAD? A TIVAD is a long hollow tube that is inserted into one of the large veins in your body. One end of the tube sits in a
More informationNormal Immunoglobulin (Human) 16%, solution for subcutaneous administration.
Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration. Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does not contain
More informationIR Central Venous Access [ ] Pre Procedure
IR Central Venous Access [1050200001] Pre Procedure Case Request/Scheduling Procedure Enter IR Case Request if not already completed (All hospitals except Grant Medical Center) [ ] Case Request IR Lab
More informationAdvancing Lives and the Delivery of Health Care. The High-Flow Port Designed for Apheresis
Advancing Lives and the Delivery of Health Care The High-Flow Port Designed for Apheresis Optimized for Long Device Life Bench Tested up to 1,000 Accesses 1 Bard is proud to introduce the first and only
More informationExtravasation emergencies: state-of-the-art management and progress in clinical research
memo (2016) 9:226 230 DOI 10.1007/s12254-016-0304-2 Extravasation emergencies: state-of-the-art management and progress in clinical research Ursula Pluschnig Werner Haslik Rupert Bartsch Robert M. Mader
More informationIntroducing the Extravasation Guidelines: EONS Toolkit Post-Symposium Report
Introducing the Extravasation Guidelines: EONS Toolkit Post-Symposium Report Introducing the Extravasation Guidelines YVONNE WENGSTRÖM New extravasation guidelines to provide advice to health care professionals
More informationThis leaflet answers some common questions about HERCEPTIN SC. It does not contain all the available information.
Consumer Medicine Information HERCEPTIN SC Trastuzumab 600 mg/5 ml solution for subcutaneous injection What is in this leaflet This leaflet answers some common questions about HERCEPTIN SC. It does not
More informationLevofloxacin infiltration treatment
Search Search Levofloxacin infiltration treatment Levaquin infiltration. A proposed algorithm for approaching the treatment of extravasation. Find patient medical information for Levofloxacin Intravenous.
More informationModule 10 Troubleshooting Guide
Module 10 Troubleshooting Guide Your safety and wellbeing are our priority. Issues can occur during your treatment and it is important that you recognize the symptoms. This guide will teach you how to
More informationAdriamycin PFS; Doxorubicin Hydrochloride For Injection, USP; Doxorubicin Hydrochloride Injection
PATIENT & CAREGIVER EDUCATION Doxorubicin (Conventional) Brand Names: US Adriamycin Brand Names: Canada Adriamycin PFS; Doxorubicin Hydrochloride For Injection, USP; Doxorubicin Hydrochloride Injection
More informationRESTORING PATENCY TO CENTRAL VENOUS ACCESS DEVICES
RESTORING PATENCY TO CENTRAL VENOUS ACCESS DEVICES Indications Venous access is poor Intravenous therapy involves venous sclerosants Ambulatory chemotherapy given as an outpatient Repeated sampling, or
More informationAC: Doxorubicin and Cyclophosphamide
PATIENT EDUCATION patienteducation.osumc.edu What is AC? It is the short name for the drugs used for this chemotherapy treatment. The two drugs you will receive during this treatment are Doxorubicin (Adriamycin
More informationChoosing the right access for long term parenteral nutrition: PICC lines or tunnelled catheters G. Goossens (BE)
ESPEN Congress Lisbon 2015 HOW TO MAKE HOME PARENTERAL NUTRITION SAFER Choosing the right access for long term parenteral nutrition: PICC lines or tunnelled catheters G. Goossens (BE) Choosing the right
More informationNOTTINGHAM CHILDREN S HOSPITAL Nursing Guideline. P07 Care and Management of Children with a Totally Implantable Venous Access Device (Portacath).
NOTTINGHAM CHILDREN S HOSPITAL Nursing Guideline P07 Care and Management of Children with a Totally Implantable Venous Access Device (Portacath). Introduction A Portacath is a central venous access device
More informationExtravasation guidelines Implementation Toolkit
Extravasation guidelines 2007 Guidelines Implementation Toolkit Contents Extravasation guidelines 2007 Introduction to the Extravasation guidelines Introduction 4 Overall Goal 4 Specific Targets and Aims
More informationTotally indwelling venous access devices
Totally indwelling venous access devices Leeds MDT. April, 2008. Totally indwelling venous access devices [online]. Department of Respiratory Medicine, St James's University Hospital, UK. Available from
More informationDocument No. BMB/IFU/40 Rev No. & Date 00 & 15/11/2017 Issue No & Date 01 & 15/11/2017
Central Venous Catheter Device Description Multi-lumen catheters incorporate separate, non-communicating vascular access lumens within a single catheter body. Minipunctur Access Sets And Trays: Used for
More informationCare of a port-a-cath
Patient information Care of a port-a-cath Ladywell Building Metabolic Medicine 0161 206 1899 All Rights Reserved 2017. Document for issue as handout. What is a port-a-cath? Why do I need a port? A port-a-cath
More informationPackage leaflet: Information for the patient. Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine
Package leaflet: Information for the patient Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine Read all of this leaflet carefully before you start taking
More informationExtravasations of Vesicant / Non- Vesicant Drugs and Evidence Based Management
International Journal of Caring Sciences 2012 May-August Vol 5 Issue 2 191 S P E C I A L P A P E R Extravasations of Vesicant / Non- Vesicant Drugs and Evidence Based Management Elif Ünsal Avdal, PhD Lecturer,
More informationThe Power of Purple* Polyurethane PICC. Patient Guide. Access Systems
The Power of Purple* Polyurethane PICC Patient Guide Access Systems Preamble Your doctor is giving you a PowerPICC* catheter so that you can easily get the intravenous (IV) medicines you need. This catheter
More informationRecognising and reducing the risk of chemotherapy extravasation
Recognising and reducing the risk of chemotherapy extravasation When chemotherapy drugs leak from the veins it can cause serious injury to the patient, greatly heighten their fears of undergoing future
More informationTreatment for diltiazem extravasation
Treatment for diltiazem extravasation The Borg System is 100 % Treatment for diltiazem extravasation Start studying Extravasation drugs. Learn vocabulary, terms, and more with flashcards, games, and other
More informationUnderstanding your HICKMAN CATHETER
Understanding your HICKMAN CATHETER Patient Information What is the purpose of this information sheet? This information sheet has been written by patients, members of the public and health professionals.
More informationFor the Patient: Neoadjuvant therapy for locally advanced breast cancer using weekly paclitaxel followed by doxorubicin and cyclophosphamide
For the Patient: Neoadjuvant therapy for locally advanced breast cancer using weekly paclitaxel followed by doxorubicin and cyclophosphamide Other names: BRLATWAC BR Breast LA Locally Advanced T A C Paclitaxel
More informationEVOGAM. Information for patients Evogam 2014 NZ Patient Brochure Update v11
EVOGAM Information for patients 11881 Evogam 2014 NZ Patient Brochure Update v11 Information for patients and caregivers about EVOGAM This booklet is designed to help you follow the training you will have
More informationHospice Skills Checklist
_ XXX-XX- Print Name Last 4 of SS # Date Completed Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values
More informationThe effect of peripherally inserted central catheter (PICC) valve technology on catheter occlusion rates - The ELeCTRiC study
J Vasc Access 22; 3 ( 4): 42-425 DOI:.53/jva.57 ORIGINAL ARTICLE The effect of peripherally inserted central catheter (PICC) valve technology on catheter occlusion rates - The ELeCTRiC study Andrew J.
More informationOncology Skills Checklist
_ XXX-XX- Print Name Last 4 of SS # Date Completed Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values
More informationA Primer on Central Venous Access: Peripherally-Inserted Central Catheters, Tunneled Catheters, and Subcutaneous Ports
Disclosures A Primer on Central Venous Access: Peripherally-Inserted Central Catheters, Tunneled Catheters, and Subcutaneous Ports No conflicts of interest relevant to this presentation Jason W. Pinchot,
More informationYou have a what, inside you?
Costal Emergency Medicine Conference You have a what, inside you? Less than mainstream medical devices encountered in the ED. Eric Ossmann, MD, FACEP Associate Professor Duke University Medical Center
More informationA Silent Chemotherapy Extravasation as the Unexpected Enemy: A Case Report
Article ID: WMC002261 2046-1690 A Silent Chemotherapy Extravasation as the Unexpected Enemy: A Case Report Corresponding Author: Prof. Esther Una Cidon, Doctor and Professor, Oncology Department, Clinical
More informationFLEXIC ATH LTD. Peripherally Inserted. Instructions n For Use.
FLEXIC ATH LTD * M/29M Peripherally Inserted Catheter Instructions n For Use This leaflet contains instructions for both stan- dard needle-introducer er and protection con- tained M/29 models, i.e., with
More informationChildren's (Pediatric) PICC Line Placement
Scan for mobile link. Children's (Pediatric) PICC Line Placement A peripherally inserted central catheter (PICC line) is most often used to deliver medication over a long period. The doctor or nurse inserts
More informationFor the Patient: ACTW Other names: BRAJACTW
For the Patient: ACTW Other names: BRAJACTW A Doxorubicin (ADRIAMYCIN ) C Cyclophosphamide T Paclitaxel (TAXOL ) weekly Uses: BRAJACTW is a drug treatment given after breast cancer surgery (called adjuvant
More informationBreast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer
Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for patients in whom anthracyclines are contraindicated or inappropriate Regimen
More informationComplications of Central Vascular Access Devices
Complications of Central Vascular Access Devices Central vascular access devices, or central venous access devices (CVADs), are fundamental in the nursing care of the critically ill, those with chronic
More informationSTEP-BY-STEP GUIDE TO SELF-INFUSION. Subcutaneous Administration of GAMMAGARD LIQUID
STEP-BY-STEP GUIDE TO SELF-INFUSION Subcutaneous Administration of GAMMAGARD LIQUID This handy guide will help you manage your subcutaneous administration of GAMMAGARD LIQUID. If you have questions on
More informationValue Life Lifecath Midli n e uide to Lifecath Midline rse s G u N A
Value Life Lifecath Midl ine A Nurse s Guide to Lifecath Midline www.vygon.co.uk vygon@vygon.co.uk Useful Information Lifecath Midline Lifecath Midline Catheter Code: 1296 Peelable Cannula Introducer
More informationVascular Disorders of the Hand Self-Assessment. Hand Vascular Disorders
Vascular Disorders of the Hand Self-Assessment 1. The patency rate of repairing a radial artery laceration with an intact palmar arch using modern microsurgical techniques is: A. 20% B. 40% C. 60% D. 80%
More informationMy patient. linetm. Help maintain quality care in the pediatric setting
My patient My my linetm linetm Help maintain quality care in the pediatric setting The role of central venous access devices in pediatric patients Central venous access devices (CVADs), also known as central
More informationPortacath Insertion. Patient Information Leaflet
Portacath Insertion Patient Information Leaflet What is a Portacath? A Portacath (also referred to as Port, Chemoport or Power Port) is an implanted central venous access device (CVAD) recommended for
More informationCarry this card with you at all times. Show this card to any medical professional treating you. Patient Implant Card. Option ELITE Vena Cava Filter.
Patient Guide A Safe Option for a Healthier You! P/N: P-2017-0175-00 Rev B 1. Static magnetic field of 3 Tesla or less. 2. Spatial gradient magnetic field of 720 Gauss/cm or less. 3. Maximum whole body
More informationProcedures/Risks:central venous catheter
Procedures/Risks:central venous catheter Central Venous Catheter Placement Procedure: Placement of the central venous catheter will take place in the Interventional Radiology Department (IRD) at The Ohio
More information40 35
NURSING GUIDE 40 35 TABLE OF CONTENTS POWERFLOW Implantable Apheresis IV Port Summary Safety Information Description... 2 Indications for Use... 3 Contraindications... 4 Warnings... 4 Precautions... 5
More informationEmergency clamp should always be readily available in case of accidental catheter fracture
Note: Please see individual policies for further information. Flushing best practice: Always use a 10 diameter syringe or larger when first accessing and when flushing vascular access device (VAD) Use
More informationBreast Pathway Group Docetaxel in Advanced Breast Cancer
Breast Pathway Group Docetaxel in Advanced Breast Cancer Indication: First-line palliative treatment, with or without trastuzumab, for advanced breast cancer in patients for whom an anthracycline is not
More informationEducation for Self Administration of Intravenous Therapy HOME IV THERAPY PICC. Portacath
HOME IV THERAPY PICC Portacath Who To contact Cardio-Respiratory Integrated Specialist Services (CRISS) Office hours 0800 1630 hours Ph: 364 0167 Weekends and after hours, phone Christchurch Hospital operator
More informationPrevention of thrombosis
Prevention of thrombosis Massimo Lamperti MD, MBA Chief of General Anaesthesia Department Anaesthesiology Institute Cleveland Clinic Abu Dhabi Clinical Professor of Anaesthesiology Cleveland Clinic Lerner
More informationHealth Bites Breast Cancer. Breast Cancer. Normal breast
Health Bites Breast Cancer Breast Cancer Normal breast The normal breast tissue varies in size and shape. The breasts rest in front of the rib cage. The breasts are made up of fatty tissue, milk ducts
More informationSTOP! Have you got the most up to date version of this policy? Always Check before reading further.
Network Guidance for the Prevention and Management of Cytotoxic Extravasation Injuries (October 09) STOP! Have you got the most up to date version of this policy? Always Check www.wales.nhs.uk/nwcn/ before
More informationFor the use of only Oncologist or a Cancer Hospital or a laboratory Doxorubicin Hydrochloride Liposome Injection 2 mg/ml KEMODOXA
For the use of only Oncologist or a Cancer Hospital or a laboratory Doxorubicin Hydrochloride Liposome Injection 2 mg/ml KEMODOXA COMPOSITION Each ml contains: Doxorubicin Hydrochloride IP...2 mg Water
More informationDirections For Use. All directions should be read before use
Directions For Use All directions should be read before use DEVICE DESCRIPTION: The CLEANER.XT Rotational Thrombectomy System is a percutaneous, 6Fr catheter based system (single piece construction) that
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ETOPOSIDE-TEVA 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION etoposide
PACKAGE LEAFLET: INFORMATION FOR THE USER ETOPOSIDE-TEVA 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION etoposide Read all of this leaflet carefully before you start using this medicine because it contains
More informationFEC: Fluorouracil, Epirubicin and Cyclophosphamide
PATIENT EDUCATION patienteducation.osumc.edu FEC: Fluorouracil, Epirubicin and Cyclophosphamide What is FEC? This is the short name for the drugs used for this chemotherapy treatment. The three drugs you
More informationTotally implantable venous devices (TIVDs) significantly
Case Report 425 Catheter Fracture and Cardiac Migration - An Unusual Fracture Site of Totally Implantable Venous Devices: Report of Two Cases Chia-Lo Chang, MD; Hong-Hwa Chen, MD; Shung-Eing Lin, MD Totally
More informationChemotherapy and the risk of extravasation
Chemotherapy and the risk of extravasation Cancer Service Patient Information Leaflet This leaflet contains important information about your treatment. Please read it and ask us if you have any queries.
More informationTYPES AND USES OF VENOUS ACCESS DEVICES
FOR HEALTHCARE PROVIDER USE ONLY. THIS INFORMATION IS FOR REFERENCE PURPOSES ONLY AND DOES NOT TYPES AND USES OF VENOUS ACCESS DEVICES PERIPHERAL DEVICES 1 Typically inserted in the hand, arm, or foot
More informationYou are being asked to take octreotide as a treatment to manage the symptoms of your cancer.
For the Patient: UGIOTLAR Symptomatic management of functional carcinoid and neuroendocrine tumours of the GI tract using Octreotide (SANDOSTATIN LAR) UGI = Undesignated, GastroIntestinal OT = Octreotide
More informationLiposomal Doxorubicin (CAELYX) Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Liposomal Doxorubicin (CAELYX) Gynaecological Cancer PROCTOCOL REF: OPHAGYNCAE (Version No: 1.0) Approved for use in: Advanced ovarian cancer second/third line treatment
More informationPVACE-BOP (Hodgkin s Lymphoma)
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate 1 Ondansetron 8mg IV / Oral vinblastine 6mg/m 2 (Max: 10mg) IV Infusion Etoposide 100mg/m 2 IV infusion Patients over 65 years by 15 min infusion
More informationHow to Set Up and Infuse Your TPN
Page 1 of 10 How to Set Up and Infuse Your TPN Important: Do not change any of the supplies listed here. Keep supplies away from children. Only your home care nurse or persons trained by Fairview Home
More informationGuidelines for prevention and management of CHEMOTHERAPY EXTRAVASATION
Guidelines for prevention and management of CHEMOTHERAPY EXTRAVASATION Please note that this policy refers to the management of extravasation of cytotoxic chemotherapy only. Refer to local Trust policies
More informationThe High-Flow Port Designed & Indicated for Apheresis
The High-Flow Port Designed & Indicated for Apheresis Advancing Lives and the Delivery of Health Care Bard is proud to introduce the first and only high-flow, power-injectable port designed and indicated
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Doxorubicin 2mg/ml Concentrate for solution for infusion Referred to in this leaflet as Doxorubicin 2mg/ml
PACKAGE LEAFLET: INFORMATION FOR THE USER Doxorubicin 2mg/ml Concentrate for solution for infusion Referred to in this leaflet as Doxorubicin 2mg/ml Read all of this leaflet carefully before you start
More informationThe Community Oncologist
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com The Community Oncologist Preventing Chemotherapy Errors Lisa
More informationInfusion Skills Competency Checklist To be used at annual skills fair or at any other time for IV Competency
Employee Profile Infusion Skills Checklist Last Name First Name Middle Initial Employee Number Employee Discipline Check one: RN LPN Per state specific LPN Practice Acts Direct Supervisor s Name: Date
More information